Evotec: Restructuring Continues
Will this work out? The Hamburg-based biotech company Evotec once again shocked the capital markets in July with a drastic downward revision of its forecast, as delayed milestone payments for the current year now point to a negative adjusted consolidated EBITDA of up to minus EUR 105 million. Analysts from renowned firms such as Deutsche Bank and Berenberg reacted skeptically and sharply slashed their price targets to between EUR 3.50 and 4.00. Although the far-reaching “Horizon” restructuring program is intended to reduce the number of global locations and cut the structural cost base by approximately EUR 75 million by the end of next year, experts say the hoped-for effects have materialized too slowly so far. For investors, this means a fundamental turnaround is being noticeably delayed, as management must first painstakingly regain lost confidence and the operational pressure on the balance sheet remains high due to ongoing cash outflows. Only robust growth in the core business of over 28%, along with a solid liquidity reserve of around EUR 466 million, currently serves as a buffer and offers speculative investors a faint hope that the share price will bottom out. The Q2 earnings report on August 13 should provide more clarity and trigger some price movements.
BioNxt Solutions: Innovative Drug Delivery Instead of Laborious Drug Discovery
BioNxt Solutions is likely to face a strategic turning point in 2026. While many biotech companies invest billions in developing new active ingredients, the Canadian-German company is pursuing a significantly more efficient approach: it aims to make existing drugs more convenient, effective, and patient-friendly through patented drug-delivery technologies. This strategy is currently gaining significant momentum. In addition to its advanced cladribine program for multiple sclerosis, the new semaglutide project is now taking center stage—and with it, one of the world’s most attractive pharmaceutical markets.
By entering the GLP-1 market, BioNxt is systematically expanding its thin-film platform toward a market that, according to Morgan Stanley estimates, could grow to approximately USD 190 billion by 2035. Unlike traditional manufacturers, BioNxt is not competing with Novo Nordisk or Eli Lilly for new active ingredients, but is focusing on an area where differentiation is likely to emerge in the future: the method of drug administration. The company is currently developing an innovative, sublingual semaglutide dissolvable film that dissolves in the mouth within a few seconds and is designed to partially bypass the gastrointestinal tract and first-pass metabolism. Especially for peptide-based active ingredients, this could offer significant advantages in terms of patient comfort, treatment adherence, and practical application. With the next phase of development now underway, formulation optimization, analytical validation, and preparations for further preclinical proof-of-concept studies are already in progress—a clear sign that what began as a technological concept has now evolved into a concrete development program.
Even more exciting is the technological foundation on which BioNxt is building this new program. The company is by no means starting from scratch but is leveraging experience gained from its cladribine program, BNT23001, which is already on the path to a human clinical trial. Pharmacokinetic studies in a porcine model showed more than 40% higher bioavailability compared to the reference tablet, Mavenclad. This advantage could not only enable lower dosages in the future but also reduce side effects and improve the therapy’s cost-effectiveness. In collaboration with its German development partner, Gen-Plus, clinical trial samples have already been produced—an important operational step toward the planned human bioequivalence study. The cladribine program is now protected by the European unitary patent in 18 EU member states, while additional intellectual property proceedings are underway in the US, Canada, Japan, and Australia, among other countries.
At the same time, management is already actively pursuing commercialization and licensing options for BNT23001 and preparing for potential industry partnerships. As a result, the company’s focus is increasingly shifting from pure research toward the commercial exploitation of its platform technology. Financially, BioNxt has recently laid the groundwork for this transition. A successful LIFE private placement raised approximately CAD 2 million for the company, to be specifically invested in research and development and the further expansion of its European operations. Should the technology confirm its advantages in human trials as well, interest from larger pharmaceutical companies in licensing or acquisition deals is likely to increase significantly. Given its very low valuation of just EUR 25 million, BioNxt is an exciting specialty stock with attractive revaluation triggers!
Bayer and Novo Nordisk: What Is Next for the Pharmaceutical Giants?
Speculation in the market flares up time and again. After years of struggling, Bayer and Novo Nordisk have stabilized their operations, and the charts are already turning upward again. Bayer has since rebounded by over 130% from its low, and Novo Nordisk is also flexing its muscles again with prices above 320 kroner or EUR 43.50. Currently, neither Bayer nor Novo Nordisk is considered a classic takeover target, as potential suitors want to see legacy liabilities disappear from the balance sheet first. Bayer recently received confirmation from the US Supreme Court that claims for damages can now only be filed in federal court. This has noticeably eased the pressure on the glyphosate front, and the streamlining of the middle management level in the pharmaceutical sector is now well underway. As a result, earnings potential is once again on the rise. All that is missing now is progress in the patent portfolio toward developing new blockbuster drugs.
At the other end of the spectrum is the Danish pharmaceutical giant Novo Nordisk, which has been the subject of speculation regarding M&A transactions for some time. Following sharp price corrections down to just under EUR 30 in March, the Danish company is slowly rebounding. Due to intensified competition in the obesity market, the company is now apparently shifting into high gear. According to analysts, management is planning acquisitions worth billions to significantly strengthen its pipeline in metabolic diseases. This could get exciting in the coming year. Investors should keep a close eye on Bayer’s Q2 earnings report on August 4, followed by Novo Nordisk’s on August 5. Things could really heat up here if the outlooks improve again.
The stock markets are racing from one all-time high to the next—despite constant pressure from geopolitical tensions and interest rate debates. The rally is being driven primarily by overheated tech giants on the NASDAQ, while the life sciences sector remains on the sidelines. But that is exactly where things are starting to heat up. Shares like BioNxt, Evotec, Bayer, and Novo Nordisk are showing the first clear signs of bottoming out. Weak visibility and delayed revenue are still weighing on sentiment, but that is often the breeding ground for the next move. From a cyclical perspective, biotech seems ripe for a comeback.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a “Transaction”). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
In this respect, there is a concrete conflict of interest in the reporting on the companies.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is also a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.